Abstract | INTRODUCTION:
Nemonoxacin , a novel non-fluorinated quinolone, exhibits potent activity against Gram-positive bacteria, including MRSA and fluoroquinolone-resistant MRSA, Gram-negative and atypical pathogens. This agent also has a reduced propensity for resistance development in many kinds of pathogens. AREAS COVERED: EXPERT OPINION: Although in vitro studies have shown promising results regarding the susceptibility to nemonoxacin of common pathogens causing CDIs, ABSSSIs and STDs, further clinical trials are needed to prove its efficacy.
|
Authors | Chung-Hao Huang, Chung-Chih Lai, Yen-Hsu Chen, Po-Ren Hsueh |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 16
Issue 2
Pg. 263-70
(Feb 2015)
ISSN: 1744-7666 [Electronic] England |
PMID | 25529577
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Quinolones
- Levofloxacin
- nemonoxacin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Chlamydia Infections
(drug therapy)
- Clostridium Infections
(drug therapy)
- Community-Acquired Infections
(drug therapy)
- Drug Therapy, Combination
- Gonorrhea
(drug therapy)
- Humans
- Levofloxacin
(therapeutic use)
- Pneumonia, Bacterial
(drug therapy)
- Quinolones
(therapeutic use)
- Skin Diseases, Bacterial
(drug therapy)
|